Suven Life Sciences Ltd Share Price Today - Suven Life Sciences Ltd Stock Price Live NSE/BSE

Suven Life Sciences Ltd

NSE: SUVEN BSE: 530239

₹210.18

(7.19%)

Fri, 24 Apr 2026, 11:51 am

MTF 5xInvest in Suven Life Sciences Ltd with 5x Leverage Buy with MTF

Market Cap51.66B

PE Ratio0

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Suven Life Sciences Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
5473.52
Net Profit
-160.75
P/B
22.50
Sector P/E
57.83
P/E
0
EV/EBITDA
0
Debt/Equity (Industry)
0.57
Interest Cover (Industry)
3.83
ROCE (Industry)
6.35
RONW (Industry)
5.62
ROE
0
ROCE
0
Debt/Equity
0
EPS (TTM)
0
Dividend Yield
0
Book Value
29.08
Interest Cover
-944.59

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends per share have been stable in the past 10 years.
Suven Life Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Suven Life Sciences's dividend is above the markets top 25% of dividend payers in India (3.08%).
Suven Life Sciences is expected to become profitable in 1 year.

Cons

The company is paying a dividend however it is incurring a loss.
Operating cash flow is negative therefore debt is not well covered.
High level of physical assets or inventory.
Venkat's remuneration is higher than average for companies of similar size in India.
Venkat's compensation has increased whilst company is loss making.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	70.15	67.36	67.36	70.27	70.27
FII	0.91	1.07	1.18	0.59	0.25
DII	4.62	3.39	3.39	0.02	0.01
Public	24.32	28.18	28.07	29.12	29.47
Government	0	0	0	0	0

Technical Analysis

RSI

69.59

MACD

17.09

50 DMA

157.17

200 DMA

191.96

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	182.38	158.49	145.10	134.60	121.21	110.71	86.82
Fibonacci	158.49	149.37	143.73	134.60	125.48	119.84	110.71
Camarilla	138.27	136.08	133.89	134.60	129.51	127.32	125.13

Pivots Level: Classic

+47.78

182.38

+23.89

158.49

+10.49

145.10

134.60

Pivot Point

LTP: 202.05

-13.40

121.21

-23.89

110.71

-47.78

86.82

Moving Average

SMAEMA

Period

Value

10-EMA
197.84
20-EMA
183.39
30-EMA
174.48
50-EMA
166.61
100-EMA
166.59
200-EMA
172.07

Announcement Date	Purpose	Action	Ex Date
29 Jan 2026	board-meetings	Quarterly Results
13 May 2025	egm
13 May 2025	agm
30 Jun 2024	agm	Annual General Meeting	31 Jul 2024
06 May 2024	agm
02 Jul 2023	agm	Annual General Meeting	03 Aug 2023
09 May 2023	agm
12 Oct 2022	rights	1:2 Rights Issue of Equity Shares	18 Oct 2022
18 Sept 2022	rights	Right Issue of Equity Shares	18 Oct 2022
17 Sept 2022	rights	Rights 1:2 @ Premium Rs 54/-	18 Oct 2022

Suven Life Sciences Ltd

Max Healthcare Institute Ltd

Narayana Hrudayalaya Ltd

Aster DM Healthcare Ltd

Fortis Healthcare Ltd

Apollo Hospitals Enterprise Ltd

Suven Life Sciences Ltd About

Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function.

Industry

Miscellaneous

Founded

1989

Headquarters

CEO

Venkateswarlu Jasti

Employees

Contact

Website

http://www.suven.com

info@suven.com; investorservices@suven.com

Phone

91-40-23541142/3311/3315

Location

#8-2-334 SDE Serene Chambers, 6 th Floor Road No 5 Avenue 7, Hyderabad, Telangana, 500034

Year	History
2017	Suven Life Sciences secured Product Patents in Canada and India. Suven Life Sciences secured Product Patents in Eurasia and Norway. Suven bags product patent for treatment of neuro diseases.
2018	Suven Life Sciences secured Product Patents in Brazil and Eurasia. Suven Life Sciences secured Product Patents in Australia and Hong Kong.
2019	Suven completed the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc. Suven Life Sciences secured Product Patents in Australia and Singapore.
2022	The company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 54 per share.
2023	Suven completed enrollment of patients to the phase-2 clinical study of SUVN-G3031 in US and Canada.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Buy	1428543	121.82	11 Jan 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	1428543	121.7	11 Jan 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	1534944	78.12	13 Sept 2023
GRAVITON RESEARCH CAPITAL LLP	Sell	1534944	78.2	13 Sept 2023
GRAVITON RESEARCH CAPITAL LLP	Buy	640960	109.64	23 Apr 2021
GRAVITON RESEARCH CAPITAL LLP	Sell	640960	109.97	23 Apr 2021
ALPHA LEON ENTERPRISES LLP	Buy	656474	104.94	17 Dec 2020
ALPHA LEON ENTERPRISES LLP	Sell	627462	105.08	17 Dec 2020
KATKAR SANJAY	Buy	688893	56.27	18 Sept 2020
ALPHA LEON ENTERPRISES LLP	Sell	761598	32.17	21 Apr 2020

Suven Life Sciences Ltd News

Suven Life Sciences clarifies price movement

Suven Life Sciences states no material events pending disclosure under SEBI regulations, attributes recent price movements to market speculation following exchange surveillance queries.

08 Apr 2026

companies

Suven Life Sciences Files Q4FY26 Compliance Certificate

Suven Life Sciences Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4FY26 to BSE and NSE, confirming proper reporting of dematerialization activities.

06 Apr 2026

companies

Suven Life Sciences Raises ₹425.70 Crore via Warrants

Suven Life Sciences successfully converted warrants into 3,17,68,764 equity shares at ₹134 each, raising total funds of ₹425.70 crore through the warrant conversion process.

06 Mar 2026

co actions results

Suven Life Sciences clarifies price movement

Suven Life Sciences Limited issued clarification to BSE stating no material events pending disclosure under SEBI regulations, attributing recent price movements to market speculation.

06 Feb 2026

stocks

Suven Life Sciences Allots Shares, Changes Leadership

Suven Life Sciences allots 44.77 lakh equity shares worth Rs 60 crore through warrant conversion and appoints new Company Secretary following resignation of incumbent officer.

29 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800